Pharmacologic Inhibition of MNKs in Acute Myeloid Leukemia

The Ras/Raf/MAPK and PI3K/Akt/mTOR pathways are key signaling cascades involved in the regulation of cell proliferation and survival, and have been implicated in the pathogenesis of several types of cancers, including acute myeloid leukemia (AML). The oncogenic activity of eIF4E driven by the Mnk kinases is a convergent determinant of the two cascades, suggesting that targeting the Mnk/eIF4E axis may provide therapeutic opportunity for the treatment of cancer. Herein, a potent and selective Mnk2 inhibitor (MNKI-85) and a dual-specific Mnk1 and Mnk2 inhibitor (MNKI-19), both derived from a thienopyrimidinyl chemotype, were selected to explore their antileukemic properties. MNKI-19 and MNKI-85 are effective in inhibiting the growth of AML cells that possess an M5 subtype with FLT3-internal tandem duplication mutation. Further mechanistic studies show that the downstream effects with respect to the selective Mnk1/2 kinase inhibition in AML cells causes G1 cell cycle arrest followed by induction of apoptosis. MNKI-19 and MNKI-85 demonstrate similar Mnk2 kinase activity and cellular antiproliferative activity but exhibit different time-dependent effects on cell cycle progression and apoptosis. Collectively, this study shows that pharmacologic inhibition of both Mnk1 and Mnk2 can result in a more pronounced cellular response than targeting Mnk2 alone. However, MNKI-85, a first-in-class inhibitor of Mnk2, can be used as a powerful pharmacologic tool in studying the Mnk2/eIF4E-mediated tumorigenic mechanism. In conclusion, this study provides a better understanding of the mechanism underlying the inhibition of AML cell growth by Mnk inhibitors and suggests their potential utility as a therapeutic agent for AML.

[1]  S. Lowe,et al.  Dissecting eIF4E action in tumorigenesis. , 2007, Genes & development.

[2]  D. Fruman,et al.  Targeting of the MNK–eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function , 2013, Proceedings of the National Academy of Sciences.

[3]  G Flandrin,et al.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.

[4]  B Johansson,et al.  Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations , 2005, Leukemia.

[5]  E. Estey,et al.  Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. , 2001, The Journal of clinical investigation.

[6]  G. Scheper,et al.  The N and C Termini of the Splice Variants of the Human Mitogen-Activated Protein Kinase-Interacting Kinase Mnk2 Determine Activity and Localization , 2003, Molecular and Cellular Biology.

[7]  J. Griffin,et al.  Role of FLT3 in leukemia. , 2002, Current opinion in hematology.

[8]  A M Martelli,et al.  Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia , 2006, Leukemia.

[9]  J. Warwicker,et al.  A Quantitative Molecular Model for Modulation of Mammalian Translation by the eIF4E-binding Protein 1* , 2001, The Journal of Biological Chemistry.

[10]  F. Khuri,et al.  Protein Phosphatase 2 A Negatively Regulates Eukaryotic Initiation Factor 4 E Phosphorylation and eIF 4 F Assembly through Direct Dephosphorylation of Mnk and eIF 4 E 1 , 2014 .

[11]  Stephen L. Abrams,et al.  Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health , 2011, Oncotarget.

[12]  N. Ahn,et al.  Signal transduction through MAP kinase cascades. , 1998, Advances in cancer research.

[13]  C. Felix,et al.  The molecular basis of leukemia. , 2004, Hematology. American Society of Hematology. Education Program.

[14]  M. Clemens.  Translational regulation in cell stress and apoptosis. Roles of the eIF4E binding proteins , 2001, Journal of cellular and molecular medicine.

[15]  M. Levis,et al.  The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond , 2014, Therapeutic advances in hematology.

[16]  J. Blenis,et al.  ERK and p38 MAPK-Activated Protein Kinases: a Family of Protein Kinases with Diverse Biological Functions , 2004, Microbiology and Molecular Biology Reviews.

[17]  T. Mak,et al.  Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development , 2010, Proceedings of the National Academy of Sciences.

[18]  A. Gingras,et al.  Translational Homeostasis: Eukaryotic Translation Initiation Factor 4E Control of 4E-Binding Protein 1 and p70 S6 Kinase Activities , 1999, Molecular and Cellular Biology.

[19]  F. Khuri,et al.  Protein phosphatase 2A negatively regulates eukaryotic initiation factor 4E phosphorylation and eIF4F assembly through direct dephosphorylation of Mnk and eIF4E. , 2010, Neoplasia.

[20]  D. Saadat,et al.  A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation , 2007, Oncogene.

[21]  D. A. Foster,et al.  Inhibition of S6 kinase suppresses the apoptotic effect of eIF4E ablation by inducing TGF-β-dependent G1 cell cycle arrest. , 2013, Cancer letters.

[22]  Varsha Gandhi,et al.  Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia. , 2011, Blood.

[23]  S. Zimmer,et al.  Translational control of malignancy: the mRNA cap-binding protein, eIF-4E, as a central regulator of tumor formation, growth, invasion and metastasis. , 2000, Anticancer research.

[24]  D. Gilliland,et al.  Molecular genetics of acute myeloid leukaemia. , 2001, Best practice & research. Clinical haematology.

[25]  M. Lako,et al.  G1 to S phase cell cycle transition in somatic and embryonic stem cells , 2008, Journal of anatomy.

[26]  S. Nagata,et al.  Mnk2 and Mnk1 Are Essential for Constitutive and Inducible Phosphorylation of Eukaryotic Initiation Factor 4E but Not for Cell Growth or Development , 2004, Molecular and Cellular Biology.

[27]  P. Purushottamachar,et al.  First Mnks degrading agents block phosphorylation of eIF4E, induce apoptosis, inhibit cell growth, migration and invasion in triple negative and Her2-overexpressing breast cancer cell lines , 2014, Oncotarget.

[28]  F. Dick,et al.  Posttranslational modifications of the retinoblastoma tumor suppressor protein as determinants of function. , 2012, Genes & cancer.

[29]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[30]  B. Hemmings,et al.  Structure, regulation and function of PKB/AKT--a major therapeutic target. , 2004, Biochimica et biophysica acta.

[31]  G. Scheper,et al.  The Mitogen-Activated Protein Kinase Signal-Integrating Kinase Mnk2 Is a Eukaryotic Initiation Factor 4E Kinase with High Levels of Basal Activity in Mammalian Cells , 2001, Molecular and Cellular Biology.

[32]  M. Walkinshaw,et al.  Synthesis and biological activity of 2-anilino-4-(1H-pyrrol-3-yl) pyrimidine CDK inhibitors. , 2004, Bioorganic & medicinal chemistry letters.

[33]  早川 文彦.  Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines , 2000 .

[34]  N. Sonenberg,et al.  Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases. , 2011, Cancer research.

[35]  Shudong Wang,et al.  Pharmacologic co-inhibition of Mnks and mTORC1 synergistically suppresses proliferation and perturbs cell cycle progression in blast crisis-chronic myeloid leukemia cells. , 2015, Cancer letters.

[36]  C. Proud,et al.  Targeting Mnks for Cancer Therapy , 2012, Oncotarget.

[37]  Sunita K. C. Basnet,et al.  Discovery of 5‐(2‐(Phenylamino)pyrimidin‐4‐yl)thiazol‐2(3H)‐one Derivatives as Potent Mnk2 Inhibitors: Synthesis, SAR Analysis and Biological Evaluation , 2014, ChemMedChem.

[38]  S. Snyder,et al.  RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[39]  C. Sherr,et al.  D-type cyclins. , 1995, Trends in biochemical sciences.

[40]  S K Burley,et al.  Hierarchical phosphorylation of the translation inhibitor 4E-BP1. , 2001, Genes & development.

[41]  K. Borden,et al.  Phosphorylation of the Eukaryotic Translation Initiation Factor eIF4E Contributes to Its Transformation and mRNA Transport Activities , 2004, Cancer Research.

[42]  I. Bernstein,et al.  Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. , 2001, Blood.

[43]  S. Gygi,et al.  Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. , 1999, Genes & development.

[44]  H. Drexler,et al.  FLT3 mutations in acute myeloid leukemia cell lines , 2003, Leukemia.

[45]  P. Pandolfi,et al.  eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression , 2010, Proceedings of the National Academy of Sciences.

[46]  C. Tribioli,et al.  Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[47]  C. Proud,et al.  MAP kinase-interacting kinases--emerging targets against cancer. , 2014, Chemistry & biology.

[48]  I. Weissman,et al.  AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[49]  M. Weiner,et al.  Identification of the human Mnk2 gene (MKNK2) through protein interaction with estrogen receptor beta. , 2000, Genomics.

[50]  F. Das,et al.  TGFβ‐induced PI 3 kinase‐dependent Mnk‐1 activation is necessary for Ser‐209 phosphorylation of eIF4E and mesangial cell hypertrophy , 2013, Journal of cellular physiology.

[51]  J. Licht,et al.  Aberrant Eukaryotic Translation Initiation Factor 4E-Dependent mRNA Transport Impedes Hematopoietic Differentiation and Contributes to Leukemogenesis , 2003, Molecular and Cellular Biology.

[52]  T. Naoe,et al.  Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines , 1997, Leukemia.

[53]  E. Raymond,et al.  New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. , 2006, Seminars in oncology.

[54]  Jonathan A. Cooper,et al.  Mitogen‐activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2 , 1997, The EMBO journal.

[55]  Min Zhang,et al.  Inhibition of Polysome Assembly Enhances Imatinib Activity against Chronic Myelogenous Leukemia and Overcomes Imatinib Resistance , 2008, Molecular and Cellular Biology.

[56]  C. Proud,et al.  Features of the Catalytic Domains and C Termini of the MAPK Signal-integrating Kinases Mnk1 and Mnk2 Determine Their Differing Activities and Regulatory Properties* , 2005, Journal of Biological Chemistry.

[57]  P. Iversen,et al.  Inhibition of Mnk kinase activity by cercosporamide and suppressive effects on acute myeloid leukemia precursors. , 2013, Blood.

[58]  K. Orita,et al.  Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23) , 1997, Leukemia.